Adam Hofmann, MD, CM, FRCPC

Summary

Adam Hofmann is a Royal College–certified general internist (FRCPC, 2009) trained at McGill University (MD, CM, 2005; internal medicine residency and general internal medicine fellowship, McGill University Health Centre, 2005–2010), where he served as chief resident in general internal medicine. He is a diplomate of the American Board of Internal Medicine, recertified in 2019. He has practiced hospital-based internal medicine continuously since 2010, principally as staff internist at Hôpital régional de Saint-Jérôme (CISSS des Laurentides) since 2012, and has taught as a clinical teacher with the Université de Montréal Faculty of Medicine since 2009, supervising general internal medicine residents. He holds active medical licenses in Ontario (CPSO Certificate #89955, independent practice since 2009), Quebec (CMQ permit 09416), and New York. He is the CEO of Impelix Health Inc., a medical device company developing wearable bioimpedance monitoring of peripheral edema.

Prior company: Algomed / Preventia Technologies (2013–2023)

Dr. Hofmann founded Algomed / Preventia Technologies, a venture-backed preventive-medicine and applied-AI health technology company, which grew to approximately 75 employees across three countries. The company was recognized as an EY Entrepreneur of the Year finalist (Quebec, Health Care) in 2019 and as an RBC Coupe des Startups national finalist in 2020. Its affiliated clinical entity, Preventia Clinics Inc. (2016–2020), operated a technology-enabled preventive-care clinic of 20 physicians in Montreal serving approximately 8,500 patients.

Following substantial staff reductions beginning in January 2023, during the broad 2022–2023 contraction in venture funding for digital-health companies, the company ceased operations on July 10, 2023, and in July 2024 made an assignment in bankruptcy under the Bankruptcy and Insolvency Act, with MNP Ltée appointed trustee under the supervision of the Superior Court of Quebec (Commercial Division, court file 700-11-022097-242). The trustee was discharged by court order on May 14, 2026, completing the administration of the estate. Related entities — including the premises holding company (1187261 B.C. ULC) and Dr. Hofmann's former professional services corporation (AEH Medical Services ULC) — entered insolvency proceedings in the same period, under the same trustee.

Dr. Hofmann resolved the personal financial consequences of the company's failure — including corporate obligations he had personally guaranteed, such as financing for the clinics' premises, which became payable in full upon the company's failure — through a proposal to his creditors under the same Act. The re-amended proposal was accepted by the required majorities of his creditors in November 2024 and approved by the Superior Court of Quebec on January 13, 2025 (court file 500-11-064589-241). In its approval order, the Court stated that Dr. Hofmann had acted in good faith, that his conduct was not in question, and that the terms of the proposal were reasonable and designed to benefit his creditors as a whole (para. 6). Although the corporate estate anticipated no distribution to ordinary creditors, a fund established by a third party during the wind-down made refunds available to clients of Algomed who had prepaid for clinical services they had not received; dozens of clients contacted the estate and accepted refunds.

Following a billing audit begun in 2017, the RAMQ concluded in May 2018 that services Dr. Hofmann had billed under two fee codes between December 2013 and May 2018 — consultation supplements and insulin-therapy teaching — did not conform to its interpretation of the specialists' billing manual, and sought repayment of approximately $530,000. Dr. Hofmann contested the decision through the arbitration process provided under the FMSQ framework agreement (Différend Dr Adam Hofmann, No. 1174-2018-01107). In an award dated December 16, 2021, the arbitration tribunal largely upheld the RAMQ's decision, principally on the ground that the billed services were not sufficiently documented in the clinical record. The tribunal expressly found that Dr. Hofmann had acted in good faith (para. 178), observed that the manual's wording on a central interpretive question was far from clear (para. 75), and noted that the RAMQ's billing review does not assess the quality or appropriateness of medical care (paras. 23–24). Dr. Hofmann sought judicial review of the award (court file 200-17-119635-223). In November 2022, the parties resolved the matter by agreement: Dr. Hofmann undertook to repay the outstanding balance — approximately $495,000 at that date — over three years without interest, and discontinued the judicial review. He made payments of approximately $15,000 per month under that agreement, repaying roughly $300,000 — over 60% of the balance — before the insolvency proceedings described below; the remainder was compromised, with his other unsecured debts, under the terms of the creditor-approved proposal. No disciplinary, civil, or criminal proceeding resulted from the audit or the arbitration.

Media coverage of the company's closure appeared in Quebec outlets in 2024–2025, addressing the company's insolvency and Dr. Hofmann's personal insolvency proceedings, and including allegations concerning both billing practices and clinical care. The arbitral and court findings described above — including the January 2025 approval order — post-date that coverage. A civil claim reported in that coverage (Superior Court of Quebec, file 700-17-020432-240) was discontinued as against Dr. Hofmann, without costs, by a discontinuance filed on July 10, 2025. None of these allegations has resulted in a disciplinary finding in any jurisdiction; Dr. Hofmann's licensure and disciplinary status can be verified directly through the public registers listed below. A detailed factual account is available on request for professional due-diligence purposes by email at hofmann.adam@gmail.com.

Professional standing — verify independently

Licensure and disciplinary history are matters of public record. Rather than take this page's word for it, consult the registers directly:

As of the review date above, Dr. Hofmann holds his licenses in good standing, with no disciplinary findings in any jurisdiction.

Primary records. The proceedings cited on this page can be verified through official sources as follows:

Copies of the documents cited on this page are available for professional due-diligence purposes on request, by email at hofmann.adam@gmail.com.

Current work

Dr. Hofmann practices inpatient internal medicine as staff internist at Hôpital régional de Saint-Jérôme (CISSS des Laurentides), where he has practiced since 2012, including ongoing CCU attending coverage, and as a locum internist in Ontario since 2026. As CEO of Impelix Health Inc., he is preparing a first-in-human study of a wearable bioimpedance system for peripheral edema monitoring at CISSS des Laurentides. He is also a co-founder of Bravella Health, a women's-health company founded in 2024, where he served as Chief Medical Officer until June 2025, when the role transitioned to a menopause-trained obstetrician-gynecologist; he remains a co-founder and clinical advisor. He has written on medicine, technology, and health policy for the Montreal Gazette and The Washington Post, and is the author of clinical publications in general internal medicine, including a 2025 systematic review of bioimpedance for peripheral edema assessment in heart failure. As a medical student he founded the Asclepius Project humanistic-medicine society, recognized with a Forces Avenir award (no longer active).

Questions raised in due diligence

Is Dr. Hofmann's medical licence active and in good standing?
Yes. He holds active licences in Ontario (CPSO Certificate #89955), Quebec (CMQ permit 09416), and New York, with no disciplinary findings in any jurisdiction. This is verifiable directly through the public registers above.

What was the RAMQ billing dispute and how did it end?
A 2017 audit of two fee codes billed between 2013 and 2018 led to a repayment claim of approximately $530,000, largely upheld on documentation grounds in a December 2021 arbitral award that expressly found Dr. Hofmann had acted in good faith. He repaid roughly 60% of the settled balance under a 2022 agreement before the remainder was resolved in court-approved insolvency proceedings.

What happened to Preventia Technologies / Algomed?
The company ceased operations in July 2023 and made an assignment in bankruptcy in July 2024 under a court-supervised trustee (MNP Ltée). A fund established by a third party made refunds available to clients who had prepaid for services not received. In approving Dr. Hofmann's related personal proposal in January 2025, the Superior Court stated that he had acted in good faith and that his conduct was not in question.

Have any court or disciplinary proceedings found against Dr. Hofmann?
No disciplinary finding exists in any jurisdiction. A civil claim (Superior Court file 700-17-020432-240) was discontinued as against him, without costs, in July 2025. Both the arbitration tribunal (2021) and the Superior Court (2025) expressly found that he acted in good faith.